

Leukaemia Section

Short Communication

i(17q) solely in myeloid malignancies

Vladimir Lj Lazarevic

Department of Hematology, Skane University Hospital, Lund University, 22185, Lund, Sweden (VLjL)

Published in Atlas Database: February 2012

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/i17qID1038.html>
DOI: 10.4267/2042/47424

This article is an update of :
Bilhou-Nabera C. i(17q) in myeloid malignancies. *Atlas Genet Cytogenet Oncol Haematol* 2000;4(1):27-28.

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2012 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

Identity

Note

An isochromosome 17 results in a loss of the short arm (17p) and duplication of the long arm (17q) leading to a single copy of 17p and three copies of 17q.

An i(17q), usually observed in a complex karyotype, has been reported in solid tumors and in various types of hematological diseases: acute myeloid leukemias and chronic myeloid leukemias, myelodysplastic syndromes and myeloproliferative neoplasms, acute lymphoid leukemias and chronic lymphoid leukemias, and Hodgkin and non-Hodgkin lymphomas.

In chronic myeloid leukemia, i(17q) is a frequent and well known secondary anomaly, either solely in 10% of cases, or with other additional anomalies, in at least another 10% of cases, in particular with +8.

It is believed that i(17q) as a sole abnormality is a distinctive clinicopathological entity with a high risk to a leukemic progression; a subset may present as de novo AML. These neoplasms have distinctive morphologic features, including multilineage dysplasia and concurrent myeloproliferative features. Isochromosome 17q usually occurs at time of blast transformation and heralds an aggressive clinical course. In the 2008 World Health Organization (WHO) classification system, myeloid neoplasms with isochromosome 17q are only briefly mentioned within the MDS/MPN category.

Clinics and pathology

Disease

Myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS)

Phenotype/cell stem origin

Previous studies on isolated i(17q) have suggested this aberration was associated with chronic myeloid abnormalities with a high rate of progression to AML; a new clinico-pathological entity in which i(17q) is the sole abnormality has been reported in a mixed myeloproliferative disorder / myelodysplastic syndrome with an aggressive course.


Etiology

i(17q) as sole cytogenetic aberration represents only 1% of cases in myeloid malignancies.

Clinics

Isolated isochromosome 17q cases can be divided into 2 distinct subgroups based on the presentation: de novo AML and MDS/MPN.

All de novo AML fit into the WHO classification of AML with myelodysplasia-related changes (with the exception of 1 mixed phenotype acute leukemia), and showed features of both myelodysplasia (pseudo-Pelger-Huet-like neutrophils, micromegakaryocytes) and myeloproliferation (splenomegaly, hypercellularity, reticulin fibrosis, osteosclerosis).



i(17q) G- banding (left) - Courtesy Jean-Luc Lai (top) and Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services (middle and bottom); and R- banding (right) - top: Editor, bottom: Courtesy Jacques Boyer

Cytology

A severe hyposegmentation of neutrophil nuclei (pseudo-Pelger Huet neutrophils (PHH)) and a prominence of the monocyte/macrophage lineage has been noted; other studies have identified an association between hyposegmented neutrophils and loss of 17p (called 17p- syndrome), always included in complex karyotypes; the i(17q) appeared to be a part of the malignant clone as demonstrated in cases available for a FISH analysis: all myeloid cell lines observed contained the abnormal i(17q), whereas none of the lymphocytes were affected. Morphologically, all showed myelodysplastic and myeloproliferative features, including pseudo-Pelger-Huet-like neutrophils, micromegakaryocytic hyperplasia, hypercellularity, fibrosis, and osteosclerosis.

Pathology

We recommend that for cases with morphologic features suggestive of isochromosome 17q, such as pseudo-Pelger-Huet-like neutrophils or micromegakaryocytes, a complete workup with ancillary studies should be performed to explore features of both myelodysplasia and myeloproliferation to better classify the disease process, including stains for reticulum and collagen, immunostains using CD61 to reveal micromegakaryocytes, CD34 and CD117 to quantify the blasts on the core biopsy, iron stain to assess storage iron and ring sideroblasts, butyrate esterase stain to quantify monocytes, and myeloperoxidase stain to determine percentage and lineage of the blasts, as well as flow cytometry immunophenotyping of the blasts, cytogenetic

analysis for the detection of isochromosome 17q, and mutational studies of common molecular markers seen in myeloid neoplasms.

Review of the peripheral blood smear and clinical records with special attention to the presence of splenomegaly may also be helpful.

Evolution


Mutational analyses showed rare mutations in NRAS (3 of 10), FLT3 (2 of 16), and JAK2 (1 of 18), and no mutations in NPM1 (0 of 15), KIT (0 of 4), and CEBPA (0 of 4).

Mutations of JAK2, FLT3, RAS, NPM1, KIT, and CEBPA are rare and appear to not play a critical role in the pathogenesis of isochromosome 17q leukemia.

Prognosis

Log-rank test, and univariate and multivariate Cox proportional hazards regression analyses to evaluate prognostic values of patients' characteristics, including age >65 years, sex, leukocytosis, anemia, thrombocytopenia, absolute monocytosis, elevated lactate dehydrogenase, elevated β_2 -microglobulin, splenomegaly, megakaryocytic hyperplasia, dysgranulocytes, dyserythrocytes, dysmegakaryocytes, increased blasts, bone thickness, cytogenetic evidence of clonal evolution, mutations of JAK2 V617F, FLT3, or NRAS, and stem cell transplantation. In the univariate analysis, log-rank test suggested that OS was significantly associated with stem cell transplantation and absolute monocytosis.

Patients with stem cell transplantation had a longer survival ($P = 0,042$), and absolute monocytosis was associated with a shorter survival ($P = 0,016$).



Kaplan-Meier curve of overall survival (OS) of patients with myeloid neoplasms and isolated isochromosome 17q is shown. The median OS of de novo acute myeloid leukemia (AML) and of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) was 14,5 months and 11,0 months, respectively.

Cytogenetics

Cytogenetics molecular

DNA sequencing of exons 2-11 of the TP53 gene, representing the entire coding region. No mutation was detected in all 14 cases assessed. None of the 13 cases tested had bcr-abl1 fusion transcripts. It has been proposed that TP53 deletion/mutation might be responsible for the unique clinicopathologic features of myeloid neoplasms associated with isochromosome 17q. We can conclude that DNA sequencing showed no mutation in the involved TP53 allele.

Genes involved and proteins

Note

The underlying molecular defect that produces the isolated i(17q) is unknown: breakage of the proximal p arm (17p11.2) with rejoining of both centromere-containing chromatids and subsequent inactivation of one centromere; breakpoints could involve important genetic material whose disruption could result in oncogene or tumor suppression gene deregulation.

In understanding the specific i(17q) phenotype, loss of genes localized on 17p were suggested as p53 (17p13.1); a direct correlation between p53 loss and PHH neutrophils was found in a series of MDS and ANLL with 17p- syndrome. However, Fioretos et al. assessed TP53 mutations in 5 Philadelphia negative myeloid neoplasms with isolated isochromosome.

17q by sequencing, and found no mutation in all 5 cases. Similarly, none of the 14 cases assessed in another series of patients demonstrated TP53 mutation.

These results suggest that there is no association between isochromosome 17q and TP53 mutations, and that another oncogene(s) at 17q and/or tumor suppressor gene(s) at 17p may play an important role in the pathogenesis of isochromosome 17q-associated myeloid neoplasms. The presence of a moderate apoptotic rate also suggests that the cytogenetically uninvolved TP53 allele is functional.

References

- Borgström GH, Vuopio P, de la Chapelle A. Abnormalities of chromosome No. 17 in myeloproliferative disorders. *Cancer Genet Cytogenet.* 1982 Feb;5(2):123-35
- Testa JR, Cohen BC. Dicentric chromosome 17 in patients with leukemia. *Cancer Genet Cytogenet.* 1986 Sep;23(1):47-52
- Becher R, Carbonell F, Bartram CR. Isochromosome 17q in Ph1-negative leukemia: a clinical, cytogenetic, and molecular study. *Blood.* 1990 Apr 15;75(8):1679-83
- Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. *Leukemia.* 1995 Mar;9(3):370-81
- Fugazza G, Bruzzone R, Puppo L, Sessarego M. Granulocytes with segmented nucleus retain normal chromosomes 17 in Philadelphia chromosome-positive chronic myeloid leukemia with i(17q) and pseudo-Pelger anomaly. A case report studied with fluorescence in situ hybridization. *Cancer Genet Cytogenet.* 1996 Sep;90(2):166-70
- Jary L, Mossafa H, Fourcade C, Genet P, Pulik M, Flandrin G. The 17p-syndrome: a distinct myelodysplastic syndrome entity? *Leuk Lymphoma.* 1997 Mar;25(1-2):163-8

Fioretos T, Strömbeck B, Sandberg T, Johansson B, Billström R, Borg A, Nilsson PG, Van Den Berghe H, Hagemeijer A, Mitelman F, Höglund M. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. *Blood*. 1999 Jul 1;94(1):225-32

Lazarević V, Djordjević V, Magić Z, Marisavljević D, Colović M. Refractory anemia with ring sideroblasts associated with *i(17q)* and mutation of the TP53 gene. *Cancer Genet Cytogenet*. 2002 Jul 1;136(1):86-9

Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. *Cancer*. 2012 Jun 1;118(11):2879-88

This article should be referenced as such:

Lazarevic VLj. *i(17q) solely in myeloid malignancies*. *Atlas Genet Cytogenet Oncol Haematol*. 2012; 16(7):498-501.
